FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:460 February 8, 2001 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Between 1982 and May 2000, the Food and Drug Administration (FDA) received reports of 431 cases of depression, suicidal ideation, suicide attempts, or suicide in U.S. patients treated with isotretinoin (Accutane, Hoffmann–LaRoche), which is indicated for the treatment of severe nodular acne. There were 37 patients who committed suicide, 24 of them while using isotretinoin and 13 after ceasing to use it. Of these patients, 31 (84 percent) were male, and their median age was 17 years (range, 13 to 32). Among those still using the drug at the time of the suicide, the median duration of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Wysowski, D. K., Beitz, J., Jick, S. S., Vasilakis-Scaramozza, C. (2001). Methodological Limitations of the Study "Isotretinoin Use and Risk of Depression, Psychotic Symptoms, Suicide, and Attempted Suicide". Arch Dermatol 137: 1102-1103 [Full Text]